NCT03867318View on ClinicalTrials.gov

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

PHASE3CompletedINTERVENTIONAL
Enrollment

621

Participants

Timeline

Start Date

April 24, 2000

Primary Completion Date

November 16, 2001

Study Completion Date

November 16, 2001

Conditions
Hypercholesterolemia
Interventions
DRUG

Atorvastatin

Atorvastatin administered orally QD as 10 mg tablets.

DRUG

Ezetimibe

Ezetimibe administered orally QD as 10 mg tablets

DRUG

Placebo for Ezetimibe

Single placebo tablet administered orally QD

DRUG

Placebo for Atorvastatin

Single placebo tablet administered orally QD

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT03867318 - Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030) | Biotech Hunter | Biotech Hunter